Literature DB >> 20133804

A role for FKBP52 in Tau protein function.

Béatrice Chambraud1, Elodie Sardin, Julien Giustiniani, Omar Dounane, Michael Schumacher, Michel Goedert, Etienne-Emile Baulieu.   

Abstract

Tau is a microtubule-associated protein, which is widely expressed in the central nervous system, predominantly in neurons, where it regulates microtubule dynamics, axonal transport, and neurite outgrowth. The aberrant assembly of Tau is the hallmark of several human neurodegenerative diseases, collectively known as tauopathies. They include Alzheimer's disease, Pick's disease, progressive supranuclear palsy, and frontotemporal dementia and parkinsonism linked to chromosome 17. Several abnormalities in Tau, such as hyperphosphorylation and aggregation, alter its function and are central to the pathogenic process. Here, we describe biochemical and functional interactions between FKBP52 and Tau. FKBP52 is a member of the FKBP (FK506-binding protein) family that comprises intracellular protein effectors of immunosuppressive drugs (such as FK506 and rapamycin). We found that FKBP52, which is abundant in brain, binds directly and specifically to Tau, especially in its hyperphosphorylated form. The relevance of this observation was confirmed by the colocalization of both proteins in the distal part of the axons of cortical neurons and by the antagonistic effect of FKBP52 on the ability of Tau to promote microtubule assembly. Overexpression of FKBP52 in differentiated PC12 cells prevented the accumulation of Tau and resulted in reduced neurite length. Taken together, these findings indicate a role for FKBP52 in Tau function and may help to decipher and modulate the events involved in Tau-induced neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20133804      PMCID: PMC2823896          DOI: 10.1073/pnas.0914957107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  High brain densities of the immunophilin FKBP colocalized with calcineurin.

Authors:  J P Steiner; T M Dawson; M Fotuhi; C E Glatt; A M Snowman; N Cohen; S H Snyder
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

2.  Tau binds to the distal axon early in development of polarity in a microtubule- and microfilament-dependent manner.

Authors:  M Kempf; A Clement; A Faissner; G Lee; R Brandt
Journal:  J Neurosci       Date:  1996-09-15       Impact factor: 6.167

Review 3.  Tau in Alzheimer's disease.

Authors:  E M Mandelkow; E Mandelkow
Journal:  Trends Cell Biol       Date:  1998-11       Impact factor: 20.808

Review 4.  Immunophilins and the nervous system.

Authors:  S H Snyder; D M Sabatini
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

Review 5.  FK506 and the role of immunophilins in nerve regeneration.

Authors:  B G Gold
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

6.  The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation.

Authors:  Béatrice Chambraud; Hamida Belabes; Virginie Fontaine-Lenoir; Arlette Fellous; Etienne Emile Baulieu
Journal:  FASEB J       Date:  2007-04-13       Impact factor: 5.191

7.  The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.

Authors:  Chad A Dickey; Adeela Kamal; Karen Lundgren; Natalia Klosak; Rachel M Bailey; Judith Dunmore; Peter Ash; Sareh Shoraka; Jelena Zlatkovic; Christopher B Eckman; Cam Patterson; Dennis W Dickson; N Stanley Nahman; Michael Hutton; Francis Burrows; Leonard Petrucelli
Journal:  J Clin Invest       Date:  2007-02-15       Impact factor: 14.808

Review 8.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders.

Authors:  Carlo Ballatore; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2007-09       Impact factor: 34.870

9.  The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development.

Authors:  M Goedert; R Jakes; R A Crowther; J Six; U Lübke; M Vandermeeren; P Cras; J Q Trojanowski; V M Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

10.  Rabbit FKBP-59/HBI does not inhibit calcineurin activity in vitro.

Authors:  M C Lebeau; I Myagkikh; N Rouvière-Fourmy; E E Baulieu; C B Klee
Journal:  Biochem Biophys Res Commun       Date:  1994-09-15       Impact factor: 3.575

View more
  51 in total

Review 1.  Organization and function of the FKBP52 and FKBP51 genes.

Authors:  Donna L Cioffi; Tina R Hubler; Jonathan G Scammell
Journal:  Curr Opin Pharmacol       Date:  2011-04-21       Impact factor: 5.547

Review 2.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.

Authors:  Janet van Eersel; Yazi D Ke; Xin Liu; Fabien Delerue; Jillian J Kril; Jürgen Götz; Lars M Ittner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

Review 4.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

Review 5.  Therapeutic Strategies for Restoring Tau Homeostasis.

Authors:  Zapporah T Young; Sue Ann Mok; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

Review 6.  FKBP51 and FKBP52 in signaling and disease.

Authors:  Cheryl L Storer; Chad A Dickey; Mario D Galigniana; Theo Rein; Marc B Cox
Journal:  Trends Endocrinol Metab       Date:  2011-08-31       Impact factor: 12.015

7.  FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications.

Authors:  N C Gassen; J Hartmann; A S Zannas; A Kretzschmar; J Zschocke; G Maccarrone; K Hafner; A Zellner; L K Kollmannsberger; K V Wagner; D Mehta; S Kloiber; C W Turck; S Lucae; G P Chrousos; F Holsboer; E B Binder; M Ising; M V Schmidt; T Rein
Journal:  Mol Psychiatry       Date:  2015-04-07       Impact factor: 15.992

8.  Loss of Hsp110 leads to age-dependent tau hyperphosphorylation and early accumulation of insoluble amyloid beta.

Authors:  Binnur Eroglu; Demetrius Moskophidis; Nahid F Mivechi
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

Review 9.  Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease.

Authors:  Laura J Blair; Jonathan J Sabbagh; Chad A Dickey
Journal:  Expert Opin Ther Targets       Date:  2014-07-29       Impact factor: 6.902

Review 10.  Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.

Authors:  Andrzej Galat
Journal:  Cell Mol Life Sci       Date:  2012-12-08       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.